SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as bulls anticipate a potential breakout past the $30 resistance level, fueled by community excitement over global GLP-1 expansion and upcoming peptide developments. While some traders debate the stock's volatility and short-term price swings, active discussions remain centered on the company's long-term growth as a digital health platform.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is seeing extreme volatility and intense community debate following the unexpected resignation of its CEO to join Truist Financial, sparking concerns over the company's strategic direction and leadership stability. While some investors view the current price as a generational value opportunity given the stock's significant decline and low valuation multiples, others fear a potential 'value trap,' citing ongoing debt concerns and skepticism regarding the company's ability to maintain growth in a competitive fintech landscape.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is facing intense selling pressure following a double miss on second-quarter earnings and revenue that triggered significant downward revisions from analysts. The community is sharply divided, with bearish voices citing weak operational performance and safety concerns, while bargain hunters and swing traders discuss potential oversold conditions and the possibility of a rebound based on historical seasonal trends.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently rallying on heavy volume, driven by investor optimism following positive Phase 3 clinical data for its gene-editing therapy and the initiation of a rolling BLA submission. The community is actively discussing a potential short squeeze, citing a high short interest and institutional accumulation, while weighing the company's long-term commercial potential against concerns regarding recent equity offerings.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft.The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently driving massive community conversation as the stock experiences extreme volatility and rapid price appreciation following its IPO. Investors are actively debating the company's multi-trillion dollar valuation against its current financial losses, with many discussing the potential for a massive short-term momentum rally versus concerns over an eventual lock-up period expiration and long-term fundamentals.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is currently experiencing heightened volatility and intense community debate as the stock navigates a period of significant technical consolidation following its rapid surge. Investors are actively analyzing a wave of recent insider selling and mixed market signals, while long-term bulls remain focused on the company's expanding AI infrastructure footprint and institutional accumulation.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba Group is facing significant selling pressure as investors grapple with its inclusion on a list of Chinese firms alleged to have ties to the military, alongside broader frustration over the stock's persistent underperformance compared to the broader market. Community discussion is sharply divided between retail bulls who view the stock as an undervalued AI and cloud leader ripe for a rebound, and vocal bears who characterize the equity as a perpetual value trap plagued by geopolitical risk and regulatory scrutiny.

Fox Corp. engages in providing television production and broadcasting services. It also provides news under the brands FOX News Media, FOX Sports, FOX Entertainment and FOX Television Stations, and Tubi Media Group. It operates through the following segments: Cable Network Programming, Television, and Other and Corporate. The Cable Network Programming segment refers to the production and licensing of news and sports content distributed primarily through traditional cable television systems, direct broadcast satellite operators, and telecommunication companies and online multi-channel video programming distributors. The Television segment focuses on the acquisition, marketing, and distribution of broadcast network programming. The Other and Corporate segment relates to the FOX Studio Lot, Credible Labs Inc, corporate overhead costs, and intracompany eliminations. The company was founded by Keith Rupert Murdoch on May 3, 2018, and is headquartered in New York, NY.

Fox Corporation - Ordinary Shares - Class A

Fox Corporation

Fox Corporation is trending as investors react to the major announcement that it will acquire Roku for $22 billion in a cash-and-stock deal. While the move signals a strategic shift into connected-TV and ad-tech, market sentiment is divided, with the community actively debating the steep purchase price, long-term synergy potential, and the risks of dilution versus the value of Roku's 100+ million household reach.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum (HQ) is experiencing a sharp surge in trading volume as investors focus on its status as a recent quantum software IPO with a low float and significant institutional backing from industry leaders like IonQ and Dell. The community is actively debating its potential as a "Microsoft of quantum computing" and comparing its patent portfolio against sector peers while keeping a close eye on technical breakout levels.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is currently a focal point for investors as the community analyzes recent clinical data and HAE portfolio progress, with discussions centered on potential M&A prospects, the navenibart trial timeline, and lingering frustrations over historical stock performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes

PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes PR Newswire WARREN, N.J., June 15, 2026 Proceeds to be used to repurchase or repay 2026 convertible...

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.

Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +93.35% and +16.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results PR Newswire...

Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for PTC Therapeutics (PTCT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.

Horizon Investments LLC Takes $3.06 Million Position in PTC Therapeutics, Inc. $PTCT

Horizon Investments LLC acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 40,333 shares of the biopharmaceutical company's stock, va...

Agenus (AGEN) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Current Price	$76.77
Prev Close	$75.14
Open	$72.03
Dividend Yield	0.00%
50-Day Moving Average	$70.42
Beta	1.16
Avg. Volume	1.39M
PE Ratio	-32.09

52-Week High	$87.50
52-Week Low	$43.18
Market Capitalization	$6.23B
EPS (Annual)	$7.78
Price to Book	-34.51
Revenue Per Employee	$1.75M

PTCTPTC Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PTCT News